title: Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
authors.forename: K Ray
authors.initials: KR
authors.lastname: Chaudhuri
authors.forename: Vandena
authors.initials: V
authors.lastname: Dhawan
authors.forename: Sumit
authors.initials: S
authors.lastname: Basu
authors.forename: Gordon
authors.initials: G
authors.lastname: Jackson
authors.forename: Per
authors.initials: P
authors.lastname: Odin
mesh_terms: D001021:Aortic Valve / Q000473:pathology*; D001971:Bromocriptine / Q000009:adverse effects*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects*; D004873:Ergolines / Q000009:adverse effects*; D005355:Fibrosis / Q000139:chemically induced*; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D001971:Bromocriptine; D000077465:Cabergoline